medRxiv preprint doi: https://doi.org/10.1101/2024.11.28.24317652; this version posted December 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# Early Diagnosis and Prognostic Prediction of Colorectal Cancer through Plasma Methylation Regions

3 Lingqin Zhu<sup>1\*</sup>, Lang Yang<sup>2,3\*</sup>, Fangli Men<sup>4\*</sup>, Jianwei Yu<sup>5\*</sup>, Shuyang Sun<sup>1</sup>, Chenguang Li<sup>1</sup>,

4 Xianzong Ma<sup>3</sup>, Junfeng Xu<sup>2,3</sup>, Yangjie Li<sup>3</sup>, Ju Tian<sup>6</sup>, Xin Wang<sup>3</sup>, Hui Xie<sup>3</sup>, Qian Kang<sup>1</sup>,

5 Linghui Duan<sup>3</sup>, Xiang Yi<sup>7</sup>, Wei Guo<sup>8</sup>, Xueqing Gong<sup>8</sup>, Ni Guo<sup>4</sup>, Youyong Lu<sup>9#</sup>, Joseph

6 Leung<sup>10#</sup>, Yuqi He<sup>1, 3#</sup>, Jianqiu Sheng<sup>2,3#</sup>

- 7 1. Department of Gastroenterology, Beijing Chest Hospital, Beijing Tuberculosis and
- 8 Thoracic Tumor Research Institute, Laboratory for Clinical Medicine, Capital
- 9 Medical University, No. 9 Beiguan Street, Tongzhou District, Beijing 101149, China
- 10 2. Senior Department of Gastroenterology, The First Medical Center of Chinese
- People's Liberation Army General Hospital, No. 28 of Fuxing Road, Haidian District,
   Beijing 100853, China;
- 13
   3. Department of Gastroenterology, Seventh Medical Center of Chinese PLA General
- 14 Hospital, No.5 Nanmencang, Dongcheng District, Beijing 100700, China;
- 15 4. Department of Gastroenterology, Dongying People's Hospital, Nan Yi Lu 317,
- 16 Dongying District, Dongying 257000, China
- 17 5. Department of Gastroenterology, Longyan First Affiliated Hospital of Fujian
- 18 Medical University, 105 Jiuyi Road (north), Longyan 364000, China
- 19 6. Department of Hepatobiliary and Pancreatic Surgery, The First Medical Center of
- 20 Chinese PLA General Hospital, Institute of Hepatobiliary Surgery and Key
- 21 Laboratory of Digital Hepetobiliary Surgery of Chinese PLA General Hospitall, No.
- 22 28 of Fuxing Road, Haidian District, Beijing 100853, China;
- 23 7. Mega Genomics Limited, 401 Health Work, North Garden Road, Haidian District,
- 24 Beijing 100083, China;
- 8. Shanghai Yingce Biotechnology Co., Ltd, Room 202, 203, 2nd Floor, No. 4, Lane
  28. Mingnan Road, Songjiang District, Shanghai 201613, China;
- 20 200, Winghan Koad, Songhang District, Shanghar 201013, Clinia,
   27 9. Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and
- 28 Translational Research (Ministry of Education), Peking University Cancer
- 29 Hospital/Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China
- 30 10. Section of Gastroenterology, Sacramento VA Medical Center, Mather, California
- 31 \*These authors contributed equally to this work.
- 32 Word count of the manuscript text (3365)
- 33 <sup>#</sup>Correspondence to:
- 34 Email: <u>youyonglu@hsc.pku.edu.cn</u>
- 35 Prof. Youyong Lu, MD, Ph.D: Laboratory of Molecular Oncology, Key Laboratory of
- 36 Carcinogenesis and Translational Research (Ministry of Education), Peking University
- 37 Cancer Hospital/Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China;
- 38 Email: ercpmaster@hotmail.com
- 39 Prof. Joseph Leung, Section of Gastroenterology, Sacramento VA Medical Center, 10535
- 40 Hospital Way, 111/G, Mather, CA 95655. Tel: (916)366-5339, Email: jwleung@ucdavis.edu
- 41 Email: endohe@163.com
- 42 Prof. Yuqi He, MD, Ph.D: Department of Gastroenterology, Beijing Chest Hospital, Capital
- 43 Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, No. 9

- 44 Beiguan Street, Tongzhou District, Beijing 101149, China; Department of Gastroenterology,
- 45 the 7<sup>th</sup> Medical Center of Chinese PLA General Hospital, No.5 Nanmencang, Dongcheng
- 46 District, Beijing 100700, China;
- 47 Email: jianqiu@263.net
- 48 Prof. Jianqiu Sheng, MD, Ph.D: Department of Gastroenterology, the 7<sup>th</sup> Medical Center of
- 49 Chinese PLA General Hospital, No.5 Nanmencang, Dongcheng District, Beijing 100700,
- 50 China. Phone: +86-10-66721299; Fax: +86-10-66721024;
- 51
- 52

#### 53 Abstract

54	The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and
55	prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there
56	are no biomarkers that serve simultaneously for early diagnosis and prognostic prediction in
57	CRC patients. Herein, we developed a plasma panel (27 DMRs, differential methylated
58	regions) and validated its superior performance across CRC diagnosis and prognosis
59	prediction in an independent cohort. We first conducted a preliminary screening of 119 CRC
60	tissue samples to identify CRC-specific methylation features. Subsequently, a CRC-specific
61	methylation panel was developed by further filtering 161 plasma samples. Then machine
62	learning algorithms were applied to develop diagnosis and prognosis models using cfDNA
63	samples from 51 CRC patients and 33 normal controls. The diagnosis model was tested in a
64	cohort consisting of 30 CRC, 37 advanced adenoma (AA), and 14 healthy plasma samples,
65	independently validated in a cohort consisting of 18 CRC, 91 NAA, 23 AA and 34 healthy
66	plasma samples. In the tissue external validation cohort (GSE48684), the cfDNA methylation
67	diagnosis model conducted with the panel, have the area under the curve (AUC) reached
68	0.983, and for the plasma cfDNA model in the external validation cohort, the sensitivities for
69	NAA, AA and CRC 0 -II are 48.4%. 52.2% and 66.7% respectively, with a specificity of 88%.
70	Additionally, the panel was applied to patient staging and metastasis, performing well in
71	predicting CRC distant metastasis (AUC = $0.955$ ) and prognosis (AUC = $0.867$ ). Using
72	normal samples as control, the changes in methylation score in both tissue and plasma were
73	consistent across different lesions, although the degree of alterations varied with severity. The
74	methylation scores vary between paired tissue and blood samples, suggesting distinct

81	Prognosis prediction
80	Keywords: Colorectal cancer; cell-free DNA Methylation; Diagnosis prediction;
79	
78	CRC patients.
77	metastasis and prognosis, ultimately enabling early intervention and risk stratification for
76	methylation models based on 27 DMRs can identify different stages of CRC and predict
75	mechanisms of migration from tumor tissue to blood for the 27 DMRs. Together, Our cfDNA

#### 83 Introduction

84	Colorectal cancer (CRC) is the third most prevalent cancer globally and ranks as the fourth
85	leading cause of cancer death, accounting for 9.4% of cancer-related mortalities <sup>(1)</sup> . When
86	patients were diagnosed with CRC, over half of their family (62.9%) faced financial burdens
87	<sup>(2, 3)</sup> . Extensive research underscores that the survival rates of individuals diagnosed with
88	advanced CRC (Stage III or IV) witness a significant decrement (4, 5). Early detection and
89	removal of precancerous lesions remain the most effective strategy to prevent CRC-associated
90	mortality <sup>(6)</sup> . While colonoscopy is regarded as the gold standard for CRC detection, its
91	limitations including invasiveness, suboptimal patient compliance and risk of complications
92	including intestinal perforation, warrant further consideration (7). Guaiac-based fecal occult
93	blood test (gFOBT), fecal immunochemical test (FIT), carcino-embryonic antigen (CEA), and
94	multi-target stool DNA (mt-sDNA) testing, are constrained in clinical application due to the
95	lower sensitivity <sup>(8, 9)</sup> .
96	Recent research demonstrated a profound correlation between CRC and the development of
97	genetic and epigenetic alterations. During early stage of CRC development, epigenetic
98	modifications surpass the frequency of gene mutations, indicating their potential as diagnostic
99	biomarkers in screening for colon polyps and cancer <sup>(10)</sup> . Circulating tumor DNA (ctDNA) in
100	cell-free DNA (cfDNA) primarily come from apoptotic and necrotic tumor cells, carrying
101	cancer-specific epigenetic alterations (11). Notably, blood cfDNA methylation emerges as a
102	promising cancer screening pathway because of its early appearance in tumorigenesis and
103	abundant signal density (12).
104	The value of cfDNA methylation in early diagnosis, detection of recurrence, molecular

105	subtyping and prognostic prediction of CRC has been proven <sup>(13)</sup> . However, there are still
106	reported limitations. One study found a diagnostic panel for CRC demonstrated great
107	performance, but it was derived from CRC tissue and normal blood leukocyte methylation
108	data, potentially introducing bias due to the inconsistent sample types (14). Another study
109	addressed the potential of cfDNA methylation in patient risk stratification, but the
110	requirement for blood sampling every three months led to poor patient compliance <sup>(15)</sup> .
111	In this study, we aimed to develop plasma biomarkers derived from CRC tissues that exhibit
112	superior performance in the diagnosis, metastasis and prognostic prediction for CRC. We
113	meticulously screened CRC and normal tissues, and refining our selection within plasma
114	samples. More importantly, the substantial proportion of paired tissue and plasma samples
115	(from the same patient), effectively minimized potential data bias. The final resulting panel
116	comprised 27 differential methylated regions (DMRs), with the area under the curve (AUC)
117	reached 0.983 in the tissue validation cohort. Given that DNA methylation markers in plasma
118	primarily stem from tumor tissues, these 27 DMRs exhibit significant potential in CRC
119	plasma diagnostics. With a single blood test, we can ascertain the presence of CRC,
120	distinguish the specific stages of the lesion (advanced adenoma, CRC 0-II, CRC III-IV), help
121	identify distant metastasis, and achieve optimal risk stratification for CRC patients. This test
122	is of clinical significance and holds promise in guiding the diagnosis and treatment for CRC.
123	

#### 124 Materials and Methods

#### 125 Study design and samples

- 126 Specific DNA methylation markers for CRC were identified through analysis of TCGA public
- 127 database data, alongside collected tissue and plasma samples. Subsequently, diagnosis,
- 128 metastasis, and prognosis models for CRC were established and validated. The 450k chip
- 129 methylation data encompassing colorectal, esophageal, gastric, lung, liver, and breast cancers,
- 130 and CRC transcriptome sequencing data were downloaded from The Cancer Genome Atlas
- 131 (TCGA) database. The methylation data of tissue validation cohort was obtained from
- 132 Fifteen pairs of tissue samples from the Seventh Medical Center of PLA General Hospital
- 133 were sequenced with the Roche Nimble Gen Seq Cap Epi method. The 89 tissue samples and
- 134 77 plasma samples used for marker screening were collected between June and December
- 135 2020 at the Seventh Medical Center of PLA General Hospital and Dongying People's Hospital.
- 136 Participants for model establishment and validation were enrolled from June 2020 to July
- 137 2022 in the Seventh Medical Center of PLA General Hospital, Dongying People's Hospital.
- 138 The paeticipants for external validation cohort were enrolled from June 2021 to December
- 139 2022 at the First Hospital of Longyan, Fujian Medical University. Inclusion and exclusion
- 140 criteria are outlined in the Supplementary Materials. Detailed methods for DNA extraction,
- 141 library construction, targeted bisulfite sequencing, and methylation data processing are
- 142 provided in the Supplementary Materials.

#### 143 CRC-specific methylation markers selection

144 Combining TCGA methylation data with our 15 pairs of tissue methylation sequencing results,

probes were designed for further screening in the 89 samples (13 normal tissues and 38 paired7

146	CRC tissues).	, 404 DMRs	were identified.	The detailed	methods were	listed in sup	plementary

- 147 methods. Then, the methylation levels of 77 plasma samples from 13 Normal, 15 non-
- 148 advanced adenoma (NAA), 12 advanced adenoma (AA) and 37 CRC participants, were
- analyzed. Subsequently, the Least Absolute Shrinkage and Selection Operator (LASSO)
- regression analysis was used to filter markers, and 27 regions that appeared in more than 50
- 151 iterations were chosen as plasma diagnostic markers. The relationship between the
- 152 methylation levels of the 27 DMRs and the transcription levels of their respective genes was
- 153 compared by Spearman correlation coefficients.
- 154 Construction of the CRC diagnosis model
- 155 The methylation data from the training cohort underwent machine learning, culminating in the
- 156 establishment of a five-fold cross-validated model characterized by binary deviance
- 157 minimization standards. The diagnosis model was constructed using logistic regression, and
- 158 its performance was evaluated through Receiver Operating Characteristic (ROC) curve
- analysis. The optimal cutoff value was determined using the maximum Youden index. The
- 160 methylation data of tissue validation cohort (GSE48684) was downloaded from GEO (Gene
- 161 Expression Omnibus) dataset. Using the methylation scores derived from the diagnosis model,
- 162 the CRC staging (AA, CRC 0-II, CRC III-IV) was predicted.

## 163 Construction of the CRC metastasis and prognosis models

- 164 Utilizing the methylation scores derived from the diagnosis model, in conjunction with patient
- 165 pathological parameters (metastasis), the plasma CRC metastasis model was constructed. The
- 166 performance of this model underwent evaluation through ROC analysis, with the optimal
- 167 cutoff value determined via the maximum Youden index. Furthermore, employing the same8

168	methodology, the plasma	prognosis model	was established a	and validated,	based on the
-----	-------------------------	-----------------	-------------------	----------------	--------------

- 169 methylation scores derived from the CRC diagnosis model and survival information from the
- 170 patients.

### 171 Statistical analysis

- 172 All statistical analyses were conducted using SPSS 26.0 or R 4.1.3. Two-sided tests were used
- 173 for p-values, with differences deemed statistically significant at P < 0.05. Model performance
- 174 was assessed through ROC analysis using the "roc" function from the R package pROC,
- 175 generating AUC and a 95% confidence interval (CI). Kaplan-Meier (KM) curves were used
- 176 for survival curve estimation, with comparisons made through the log-rank test and hazard
- 177 ratios determined by Cox regression.

#### 179 **Results**

#### 180 **Patient characteristics**

- 181 To delineate DNA methylation biomarkers specific to CRC, 119 tissues and 77 plasma
- 182 samples (originating from the same patients with tissues) were collected for methylation
- 183 sequencing analysis, narrowing down to 142 DMRs. Then the 27 DMRs were selected with
- 184 the sequencing data of 84 plasma samples. Following this, CRC diagnosis, metastasis, and
- 185 prognosis models were constructed using plasma samples from 84 individuals (51 CRC, 33
- 186 Normal). Validation was then carried out in an independent cohort (30 CRC, 37 AA, 14
- 187 Normal). The CRC diagnosis model was further tested in an external validation cohort (18
- 188 CRC 0-II, 91 NAA, 23 AA, 34 Normal). Detailed information about the study design is
- 189 illustrated in Figure 1, and comprehensive patient characteristics are summarized in Table s2-
- 190 4.

#### 191 Methylation markers selection

192	Analyzing the 4	450k chip 1	methylation	data from	TCGA, the	differential	l methylated	sites
-----	-----------------	-------------	-------------	-----------	-----------	--------------	--------------	-------

- 193 (DMCs) in CRC were identified (Figure s1A). Combining with additional CRC-related
- 194 methylation sites reported in the literature, 1438 DMCs were selected for validation. The heat
- 195 map depicted the methylation levels of 1438 DMCs, revealing distinct methylation patterns
- 196 between Normal and Tumor. (Figure s1B). The top 1400 DMCs were carefully selected based
- 197 on the results of DNA methylation sequencing of 15 paired tissue samples (Figure s2A-C).
- 198 The distribution of the DMCs was predominantly observed in introns and promoters,
- 199 signifying substantial implications for gene expression and cellular functions (Figure s2D).
- 200 Merging the 1438 DMCs with the 1400 DMCs for probe design, 404 DMRs were discerned 10

201	across 89 tissues (Figure s3A). The different methylation patterns between Normal and Tumor
202	were also quite evident (Figure s3B-C). These DMRs correspond to genes that play pivotal
203	roles in biological processes such as cell-cell adhesion, digestive system development, and
204	cAMP and cGMP pathways (Figure s3D). Subsequently, 142 regions remained after
205	sequencing 77 plasma samples (Figure s3E-F). The final 27 DMRs were selected after
206	analyzing methylation data of the training cohort samples. Detailed information of the 27
207	DMRs is provided in Table s5. Correlation analysis revealed the methylation levels of the
208	majority of the 27 DMRs are correlated with the transcription levels of their respective genes
209	(Figure s4).
210	Development and validation of the CRC diagnosis model
211	Using methylation data from 27 DMRs in tissues, we applied machine learning to construct a
212	diagnosis model for CRC and the AUC reached a high value of 0.994 (Figure 2A). In the
213	external tissue independent validation cohort (GSE48684), the AUC for CRC is 0.983 and for
214	AA is 0.966. (Figure 2B-C). The sensitivities for AA and CRC were 95% and 94%,
215	respectively (Figure 2D-E). Besides, the plasma-based diagnosis model for CRC was
216	constructed with training cohort and validated in an external independent validation cohort,
217	the 27 DMRs exhibited distinctive methylation patterns between CRC and normal individuals
218	(Figure 3A-B). The methylation scores of the model were significantly elevated in the CRC
219	group compared to the normal and AA groups ( $P < 0.001$ ), and they increased with advance
220	tumor staging (Figure 3H). In the training cohort, the ROC curve analysis showed an AUC
221	value of 0.928 [95% confidence interval (CI): 0.874-0.981] (Figure 3C). The sensitivities of
222	the CRC diagnosis model in the training cohort for stages 0-II, III-IV, and all CRC stages 11

223	were 80%, 92%, and 86%, respectively, with a specificity of 85% (Figure 3I). ROC curve
224	analysis in the validation cohort showed AUC values for AA, stages 0-II, III-IV, and all CRC
225	stages as 0.714 (0.550–0.878), 0.890 (0.749–1.000), 0.967 (0.899–1.000), and 0.929 (0.827–
226	1.000). (Figure 3D-G). The CRC diagnosis model demonstrated a specificity of 93% in the
227	validation cohort, with sensitivities for AA, stages 0-II, III-IV, and all CRC stages of 43%,
228	67%, 100%, and 83%, respectively (Figure 3I). We further tested the early diagnostic
229	performance of the model in an external validation cohort, and the results showed that the
230	model achieved a sensitivity of 52% for AA and 48% for NAA (Figure 4A-E),
231	The plasma diagnosis model also serves to discern the specific staging of CRC patients. ROC
232	curve analysis on the validation cohort revealed an AUC of 0.813 (0.656-0.970) for
233	discriminating between CRC 0-II and CRC III-IV, and an AUC of 0.799 (0.693–0.905) for
234	distinguishing between AA and CRC (Figure s5A-C). Kaplan-Meier survival curves revealed
235	a significant reduction in overall survival (OS) for CRC III-IV patients compared to CRC 0-II
236	patients identified by this diagnosis model (Figure s5D-E).
237	Development and validation of the CRC metastasis and prognosis models
238	Through an analysis of the relationship between the methylation scores in the diagnosis model
239	of CRC patients' plasma samples and clinical-pathological parameters, we observed that
240	methylation scores are associated with metastasis and staging ( $P$ < 0.001, Figure 5A-B), but
241	not with age, gender, and lesion location ( $P$ >0.05, Figure s6A-C). This suggests the possible
242	role of 27 DMRs in metastasis and prognosis prediction. Therefore, we developed plasma-
243	based CRC metastasis and prognosis models based on the 27 CRC-specific DMRs. In the
244	training and validation cohorts, the metastasis model demonstrated high AUCs of 0.969 (95% 12

245	CI: 0.926-1) and 0.955 (95% CI: 0.878-1), respectively (Figure 5C). Methylation scores of
246	M1-CRC individuals identified from the metastasis model were significantly higher than M0-
247	CRC individuals (Figure s6D). Additionally, the M1-CRC patients exhibited shorter OS than
248	M0-CRC patients. (Figure s6E-F). For the prognosis model, ROC curves demonstrated
249	excellent performance in the training cohort (AUC = $0.883$ , 95% CI: $0.778-0.988$ ) and
250	validation cohort (AUC = $0.867$ , $95\%$ CI = $0.728-1$ ). (Figure 5D). Furthermore, Kaplan-Meier
251	survival curves revealed a significant reduction in OS for the high-risk group of CRC patients
252	identified by this prognosis model (Figure 5E). Based on the cutoff value determined by the
253	algorithm, we divided CRC patients into high-risk and low-risk groups. Notably, almost all
254	patients who developed distant metastases and those who had died belonged to the high-risk
255	group (Figure 5F, H). We further characterized the survival status distribution and metastasis
256	status between the two groups. As expected, the high-risk group had a higher proportion of
257	deceased individuals, while non-metastatic patients were more prominent in the low-risk
258	group (Figure 5G, I). These results indicate that the metastasis and prognosis models
259	successfully identified patients who require further treatment. Multivariate regression analysis
260	revealed a substantial correlation between the methylation score of the 27 DMRs and OS,
261	indicating methylation score as an independent prognostic factor for CRC (Table s6). These
262	findings underscore the considerable potential of the prognosis model based on the 27 DMRs
263	specific to CRC in predicting the prognosis and conducting risk stratification for CRC
264	patients.
265	Changes in methylation scores of tissue and plasma samples across different populations

Collectively, the CRC diagnosis model, established based on the methylation levels in these
 13

267	27 DMRs within tissues, exhibits robust performance. However, the plasma-based diagnosis
268	model exhibited reduced performance in AA and CRC 0-II compared to CRC III-IV.
269	Therefore, we analyzed the methylation scores of the 27 DMRs generated from diagnosis
270	models in paired tissue and plasma samples. Notably, in tissues, the methylation scores are
271	ranked as AA > CRC > Normal (Figure 6A), suggesting significant alterations in the
272	methylation of the 27 DMRs at the onset of precancerous lesions. In plasma, methylation
273	scores gradually increase with CRC progression (CRC III-IV > CRC 0-II > AA > Normal,
274	Figure 6B). Further analysis of individual DMR methylation levels in the blood revealed
275	discernible distinctions in certain DMRs during both AA and CRC 0-II stages, while
276	variances in another subset of DMRs became detectable exclusively during CRC III-IV stages
277	(Figure 6C). We then conducted a gene analysis of DMRs identifiable in early-stage CRC
278	blood on the Metascope website. Our findings revealed their association with processes such
279	as "secretion by cell" and "cell-cell adhesion." (Figure s6G) Consequently, we hypothesize
280	that although alterations of 26 DMRs were observed in AA tissues, only a selected few are
281	actively released into the bloodstream through cell secretion by tumor cells. The majority of
282	these alterations are likely to be identified in the blood only after the occurrence of apoptosis
283	or necrosis in tumor cells. These results elucidate the inconsistency in the performance of
284	tissue and plasma diagnosis models and the differences in diagnostic efficacy for different
285	CRC stages using the same model.
286	

#### 287 Discussion

288	Liquid biopsy of cfDNA has become an ideal clinical detection method because it is
289	minimally invasive and easily sampled. However, due to the low concentration of ctDNA in
290	bodily fluids and the heterogeneity of tumor cells, many DNA markers for CRC currently lack
291	certainty whether they originate from CRC tissues. In this study, we integrated TCGA tissue
292	data with self-collected tissue methylation data to identify CRC-related methylation sites.
293	Probes were designed and applied in paired tissue and plasma samples to further screen the
294	methylation sites. We successfully determined 27 DMRs originating from CRC tissues, which
295	were subsequently used to construct diagnostic model. In the validation cohorts of tissue and
296	plasma samples, the diagnosis models based on the 27 DMRs we established could effectively
297	differentiate samples between CRC and normal participants, in addition, the plasma diagnosis
298	model could distinguish the different stages of CRC. Furthermore, the transfer prognosis
299	model, established based on diagnosis model scores, could effectively demonstrate whether
300	the CRC had metastasized, separating CRC patients into high-risk and low-risk groups.
301	Several blood-based methylation biomarker candidates have been proposed for early
302	detection of CRC. For instance, the FDA-approved circulating methylated SEPT9 DNA
303	(mSEPT9) demonstrates sensitivities of 11.2%, 35.0%, 63.0%, 46.0%, and 77.4% for AA and
304	CRC stages I-IV, respectively, with a specificity of 91.5% (16). In a recent study, a cfDNA
305	methylation-based CRC screening model has a sensitivity of 86.4% and a specificity of 90.7%,
306	utilizing 149 markers derived from blood samples (17). In our study, 27 markers were selected
307	through a layered screening process from tissue and plasma, undergoing marker selection,
308	model development, and validation to ensure model robustness. Then the superior

309	performance of our plasma diagnosis model was validated, with a sensitivity of 83.3% and
310	specificity of 92.9%. Notably, the sensitivity for AA and NAA reached 52.2% and 48.4%
311	respectively, far surpassing the 11.2% sensitivity of mSEPT9 and the 33.3% reported in
312	another blood screening study. <sup>(16, 17)</sup> . In summary, our diagnostic model performs well in
313	detecting precancerous lesions of CRC and has the potential to become a screening method
314	for high-risk populations of CRC.
315	In plasma, we observed the methylation scores of 27 DMRs gradually increase with CRC
316	progression. It is possibly due to less vascular infiltration in early CRC <sup>(18, 19)</sup> . On the other
317	hand, the ctDNA detected in the blood of early-stage CRC is largely derived from tumor cells
318	actively secreting into the bloodstream, making it challenging to be precisely captured with
319	current detection technologies due to the limited quantity. Conversely, ctDNA in the blood of
320	late-stage CRC primarily emanated from apoptotic and necrotic tumor cells, resulting in a
321	larger quantity that facilitates easier detection. However, in reality, the methylation scores of
322	the 27 DMRs have indeed exhibited noticeable changes in AA and early cancerous tissues.
323	Additionally, in the tissue diagnosis model using the 27 DMRs, the sensitivity was 94% and
324	the specificity was 100%. Therefore, we have grounds to believe that the 27 DMRs detected
325	in plasma originate from CRC tumor tissues. With the implementation of more sensitive
326	detection methods, the performance of these 27 DMRs in early CRC plasma diagnosis is
327	likely to be further enhanced.
328	Additionally, cfDNA contributes to risk stratification and early recurrence detection in
329	CRC <sup>(20)</sup> . However, current methods rely on continuous blood cfDNA testing by patients <sup>(15, 21)</sup> .
330	This study discovered that the preoperative cfDNA methylation level of 27 DMRs is linked to 16

331	distant metastasis and is valuable for predicting the prognosis of CRC, consistent with certain
332	prior research. (22, 23). Our model predicted AUCs of 0.955 and 0.867 for distant metastasis and
333	prognosis in CRC, respectively. This underscores the potential utility of the preoperative
334	application of this cfDNA methylation model for risk stratification, serving as an effective
335	tool to improve the perioperative management of CRC patients.
336	The treatment strategies for CRC differ significantly across various stages. Molecular
337	stratification approaches for CRC patients are on the rise, and concurrently, the clinical
338	application of biomarkers to determine treatment decisions is gradually gaining traction <sup>(24)</sup> .
339	Studies have demonstrated the precise identification of T1 CRC patients at risk of lymph node
340	metastasis using a specific set of miRNAs, thereby potentially mitigating unnecessary
341	overtreatment <sup>(25, 26)</sup> . Our CRC diagnosis model, with an AUC of 0.813 for distinguishing
342	CRC 0-II from CRC III-IV, could also serve as a potent, straightforward, and cost-effective
343	preoperative screening/detection method, guiding patients to select more appropriate
344	treatment plans.
345	DNA methylation regulates gene transcription, guiding the progression from normal mucosa
346	to AA and ultimately CRC. This process involves silencing tumor suppressor genes and
347	activating oncogene transcription (27). Gene transcription levels correlate notably with
348	methylation levels at specific sites, consistent with our research findings. Additionally, several
349	genes housing the identified 27 DMRs have been partially explored in CRC. Some genes
350	contribute to tumor growth. For instance, high methylation and diminished expression of
351	transmembrane protein 240 (TMEM240) regulate CRC cell proliferation, predicting poor
352	prognosis <sup>(28)</sup> . The transcription factor homeobox A3 (HOXA3) activates aerobic glycolysis, 17

353	promoting tumor growth <sup>(29)</sup> . KIFC3 controls mitotic spindle assembly initiation <sup>(30)</sup> . Moreover,
354	several genes are implicated in tumor metastasis, such as NOVA alternative splicing regulator
355	1 (NOVA1), which promotes CRC migration by activating the Notch pathway <sup>(31)</sup> . Protein
356	tyrosine phosphatase receptor type T (PTPRT) contributes to early CRC dissemination <sup>(32)</sup> .
357	SPARC-related modular calcium binding 2 (SMOC2) serves as the distinctive signature of
358	cancer stem cells (CSCs) in CRC and promotes epithelial-to-mesenchymal transition (EMT)
359	<sup>(33, 34)</sup> . Increased methylation and expression of pancreatic and duodenal homeobox 1 (PDX1)
360	facilitate CRC invasion and migration <sup>(35)</sup> . However, the mechanisms by which alterations in
361	specific DNA methylation impact gene expression are intricate. Certain transcription factors
362	selectively recognize sequences with methylated CpG (mCpG) and influence the expression
363	of multiple genes <sup>(36)</sup> . Further exploration of the potential functional mechanisms of these
364	DNA methylation markers may deepen our understanding of the molecular processes
365	underlying CRC development, offering promising therapeutic targets.
366	This study has certain limitations. Firstly, although obtained from multiple institutions, the
367	small sample size was insufficient. Therefore, the cfDNA methylation model should be
368	further validated in large-sample trials in the future. Secondly, a prospective study is
369	necessary to compare or combine the cfDNA methylation model with clinically commonly
370	used markers such as CEA and CA19-9.
371	In conclusion, our cfDNA methylation model based on 27 DMRs can identify different stages
372	of CRC, predict metastasis and prognosis, and ultimately achieve early intervention and risk
373	stratification for CRC patients. The preoperative application of our DNA methylation
374	biomarker as a robust, convenient, and cost-effective detection method can contribute to 18

375 making more informed clinical decisions and improving the perioperative management of

- 376 CRC patients.
- 377

#### 378 AUTHOR CONTRIBUTIONS

- 379 Yuqi He and Jianqiu Sheng conceived and designed the study. Lang Yang, Fangli Men,
- Jianwei Yu, Xianzong Ma, Junfeng Xu, Yangjie Li, Ju Tian, Hui Xie, Qian Kang, Linghui
- 381 Duan, Xiang Yi, Wei Guo, Ni Guo collected the samples and curated the date. Xueqing Gong,
- 382 Lingqin Zhu, Lang Yang, Fangli Men, Jianwei Yu, Shuyang Sun, Chenguang Li, Xianzong
- 383 Ma, Junfeng Xu, Yangjie Li, Xiang Yi, Wei Guo, Ni Guo, Youyong Lu, Joseph Leung, Yuqi
- 384 He and Jianqiu Sheng analysed the data. Lingqin Zhu wrote the manuscript with the
- assistance of Youyong Lu, Joseph Leung, Yuqi He and Jianqiu Sheng.

#### 386 ACKNOWLEDGEMENTS

- 387 This research was funded by grants from the National Natural Science Foundation of China
- 388 (Grant no. 82273245), the Capital's Funds for Health Improvement and Research (Grant no.
- 389 2022-1-5082), and the Beijing Natural Science Foundation (Grant no. 7212107), Sponsored
- 390 by Dongying City Natural Science Foundation (Grant no. 2023ZR026), Sponsored by
- 391 Longyan City Science and Technology Plan Project (Grant no. 2022LYF17082).

#### **392 CONFLICT OF INTEREST STATEMENT**

393 The authors declare no conflict of interest.

#### 394 DATA AVAILABILITY STATEMENT

- 395 All of the data supporting this work will be made available from the corresponding author
- 396 upon reasonable request.

### 397 ETHICS APPROVAL AND CONSENT TO PARTICIPATE

- 398 The study was conducted in accordance with the Declaration of Helsinki, and approved by the
- 399 Ethics Committee of the Seventh Medical Center of PLA General Hospital (Approval No.
- 400 2016-70, 2020-78), Dongying People's Hospital (Approval No. DYYW-2019-002-01), and
- 401 the First Hospital of Longyan, Fujian Medical University (Approval No. 2021-k0001).
- 402 Informed consents were obtained from all participants involved in the study.

404 REFERENCES

405 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer 1. 406 Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 407 Countries. CA Cancer J Clin. 2021;71(3):209-49. Epub 2021/02/05. doi: 10.3322/caac.21660. PubMed 408 PMID: 33538338.

409 Ghazal LV, Abrahamse P, Ward KC, Morris AM, Hawley ST, Veenstra CM. Financial Toxicity and Its 2. 410 Association With Health-Related Quality of Life Among Partners of Colorectal Cancer Survivors. JAMA 411 network open. 2023;6(4):e235897. Epub 2023/04/07. doi: 10.1001/jamanetworkopen.2023.5897. 412 PubMed PMID: 37022684; PubMed Central PMCID: PMCPMC10080378 National Cancer Institute (NCI) 413 during the conduct of the study. Mr Abrahamse reported receiving grants from the National Institutes 414 of Health during the conduct of the study and outside the submitted work. No other disclosures were 415 reported.

416 Herriges MJ, Shenhav-Goldberg R, Peck JI, Bhanvadia SK, Morgans A, Chino F, et al. Financial 3. 417 Toxicity and Its Association With Prostate and Colon Cancer Screening. Journal of the National 418 Comprehensive Cancer Network : JNCCN. 2022;20(9):981-8. Epub 2022/09/09. doi: 419 10.6004/jnccn.2022.7036. PubMed PMID: 36075394.

420 Olivier T, Prasad V. Molecular testing to deliver personalized chemotherapy recommendations: 4. 421 risking over and undertreatment. BMC medicine. 2022;20(1):392. Epub 2022/11/10. doi: 422 10.1186/s12916-022-02589-6. PubMed PMID: 36348413; PubMed Central PMCID: PMCPMC9644653.

423 Patel SG, Karlitz JJ, Yen T, Lieu CH, Boland CR. The rising tide of early-onset colorectal cancer: a 5. 424 comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early 425 detection. The lancet Gastroenterology & hepatology. 2022;7(3):262-74. Epub 2022/01/30. doi: 426 10.1016/s2468-1253(21)00426-x. PubMed PMID: 35090605.

427 He X, Hang D, Wu K, Nayor J, Drew DA, Giovannucci EL, et al. Long-term Risk of Colorectal Cancer 6. 428 After Removal of Conventional Adenomas and Serrated Polyps. Gastroenterology. 2020;158(4):852-429 61.e4. Epub 2019/07/16. doi: 10.1053/j.gastro.2019.06.039. PubMed PMID: 31302144; PubMed 430 Central PMCID: PMCPMC6954345.

431 7. Hayman CV, Vyas D. Screening colonoscopy: The present and the future. World J Gastroenterol. 432 2021;27(3):233-9. Epub 2021/02/02. doi: 10.3748/wjg.v27.i3.233. PubMed PMID: 33519138; PubMed 433 Central PMCID: PMCPMC7814366.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool 434 8. 435 DNA testing for colorectal-cancer screening. The New England journal of medicine. 436 2014;370(14):1287-97. Epub 2014/03/22. doi: 10.1056/NEJMoa1311194. PubMed PMID: 24645800.

437 Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, et al. Advances in Fecal Occult 9. 438 Blood Tests: the FIT revolution. Digestive diseases and sciences. 2015;60(3):609-22. Epub 2014/12/11. 439 10.1007/s10620-014-3445-3. PubMed PMID: doi: 25492500; PubMed Central PMCID: 440 PMCPMC4366567.

441 10. Okugawa Y, Grady WM, Goel A. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. 442 Gastroenterology. 2015;149(5):1204-25.e12. Epub 2015/07/29. doi: 10.1053/j.gastro.2015.07.011. 443 PubMed PMID: 26216839; PubMed Central PMCID: PMCPMC4589488.

444 11. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nature reviews Cancer. 2011;11(6):426-37. Epub 2011/05/13. doi: 10.1038/nrc3066. PubMed PMID: 445 446 21562580.

medRxiv preprint doi: https://doi.org/10.1101/2024.11.28.24317652; this version posted December 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

12. Zeng C, Stroup EK, Zhang Z, Chiu BC, Zhang W. Towards precision medicine: advances in 5hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. Cancer communications (London,
England). 2019;39(1):12. Epub 2019/03/30. doi: 10.1186/s40880-019-0356-x. PubMed PMID:
30922396; PubMed Central PMCID: PMCPMC6440138.

Malla M, Loree JM, Kasi PM, Parikh AR. Using Circulating Tumor DNA in Colorectal Cancer:
Current and Evolving Practices. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology. 2022;40(24):2846-57. Epub 2022/07/16. doi: 10.1200/jco.21.02615. PubMed PMID:
35839443; PubMed Central PMCID: PMCPMC9390824.

Luo H, Zhao Q, Wei W, Zheng L, Yi S, Li G, et al. Circulating tumor DNA methylation profiles
enable early diagnosis, prognosis prediction, and screening for colorectal cancer. Science translational
medicine. 2020;12(524). Epub 2020/01/03. doi: 10.1126/scitranslmed.aax7533. PubMed PMID:
31894106.

459 15. Mo S, Ye L, Wang D, Han L, Zhou S, Wang H, et al. Early Detection of Molecular Residual Disease 460 and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation. JAMA 461 oncology. 2023;9(6):770-8. Epub 2023/04/20. doi: 10.1001/jamaoncol.2023.0425. PubMed PMID: 462 37079312; PubMed Central PMCID: PMCPMC10119774 Genomics (Shanghai) Ltd. Dr H. Wang 463 reported being an employee of Singlera Genomics (Shanghai) Ltd and having a patent pending for 464 202180000598.2. Dr Liu reported being an employee of Singlera Genomics (Shanghai) Ltd and having 465 a patent pending for 202180000598.2. No other disclosures were reported.

466 16. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective
467 evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut.
468 2014;63(2):317-25. Epub 2013/02/15. doi: 10.1136/gutjnl-2012-304149. PubMed PMID: 23408352;
469 PubMed Central PMCID: PMCPMC3913123.

T. Zhao F, Bai P, Xu J, Li Z, Muhammad S, Li D, et al. Efficacy of cell-free DNA methylation-based
blood test for colorectal cancer screening in high-risk population: a prospective cohort study.
Molecular cancer. 2023;22(1):157. Epub 2023/09/29. doi: 10.1186/s12943-023-01866-z. PubMed
PMID: 37770864; PubMed Central PMCID: PMCPMC10538018.

474 18. Cho SS, Park JW, Kang GH, Kim JH, Bae JM, Han SW, et al. Prognostic Impact of Extramural
475 Lymphatic, Vascular, and Perineural Invasion in Stage II Colon Cancer: A Comparison With Intramural
476 Invasion. Diseases of the colon and rectum. 2023;66(3):366-73. Epub 2022/03/26. doi:
477 10.1097/dcr.00000000002339. PubMed PMID: 35333785.

Hanrahan V, Currie MJ, Gunningham SP, Morrin HR, Scott PA, Robinson BA, et al. The angiogenic
switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenomacarcinoma sequence during colorectal cancer progression. The Journal of pathology. 2003;200(2):18394. Epub 2003/05/20. doi: 10.1002/path.1339. PubMed PMID: 12754739.

Zhou H, Zhu L, Song J, Wang G, Li P, Li W, et al. Liquid biopsy at the frontier of detection,
prognosis and progression monitoring in colorectal cancer. Molecular cancer. 2022;21(1):86. Epub
2022/03/27. doi: 10.1186/s12943-022-01556-2. PubMed PMID: 35337361; PubMed Central PMCID:
PMCPMC8951719.

Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of Plasma CellFree DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA oncology.
2019;5(8):1124-31. Epub 2019/05/10. doi: 10.1001/jamaoncol.2019.0528. PubMed PMID: 31070691;
PubMed Central PMCID: PMCPMC6512280 Balcioglu, Hafez, Goel, Rabinowitz, Billings, Swenerton,

medRxiv preprint doi: https://doi.org/10.1101/2024.11.28.24317652; this version posted December 5, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpendicular.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Aleshin, Lin, and Zimmermann, Messrs Sethi, Srinivasan, Olson, and Dashner, and Ms Navarro, reported receiving support from Natera Inc outside the submitted work. Dr Billings reported receiving support from Trovagene, OmniSeq, MissionBio, and Metastat outside the submitted work. Dr Zimmermann has a pending patent for Provisional. Dr Lindbjerg Andersen reported receiving grants from Novo Nordisk Foundation, Danish Council for Strategic Research, Danish Council for Independent Research, and Danish Cancer Society during the conduct of the study. No other disclosures were reported.

497 22. Tie J, Wang Y, Cohen J, Li L, Hong W, Christie M, et al. Circulating tumor DNA dynamics and 498 recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: 499 A prospective cohort study. PLoS medicine. 2021;18(5):e1003620. Epub 2021/05/04. doi: 500 10.1371/journal.pmed.1003620. PubMed PMID: 33939694; PubMed Central PMCID: 501 PMCPMC8128260 following competing interests: BV, KWK, & NP are founders of, and hold equity in 502 Thrive Earlier Detection and Personal Genome Diagnostics. KWK & NP are on the Board of Directors of, 503 and consultants to, Thrive Earlier Detection. KWK & BV are consultants to Sysmex, Eisai, Personal 504 Genome Diagnostics and CAGE Pharma and hold equity in CAGE Pharma. KWK, BV, and NP are 505 consultants to and hold equity in NeoPhore. BV is a consultant to and holds equity in Catalio Capital 506 Management. NP is an advisor to and holds equity in CAGE Pharma. The companies named above, as 507 well as other companies, have licensed previously described technologies related to the work 508 described in this paper from Johns Hopkins University. BV, KWK, and NP are inventors on some of 509 these technologies. Licenses to these technologies are or will be associated with equity or royalty 510 payments to the inventors as well as to Johns Hopkins University. CT and the University are entitled to 511 royalty distributions related to technology licensed to Thrive Earlier Detection. CT is a consultant to 512 Thrive. The terms of all these arrangements are being managed by Johns Hopkins University in 513 accordance with its conflict of interest policies. All other authors declare no competing interests.

Solution
Sol

518 24. Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in
519 complexity. Nature reviews Clinical oncology. 2020;17(1):11-32. Epub 2019/07/11. doi:
520 10.1038/s41571-019-0241-1. PubMed PMID: 31289352; PubMed Central PMCID: PMCPMC7577509.

521 25. Miyazaki K, Wada Y, Okuno K, Murano T, Morine Y, Ikemoto T, et al. An exosome-based liquid 522 biopsy signature for pre-operative identification of lymph node metastasis in patients with 523 pathological high-risk T1 colorectal cancer. Molecular cancer. 2023;22(1):2. Epub 2023/01/08. doi: 524 10.1186/s12943-022-01685-8. PubMed PMID: 36609320; PubMed Central PMCID: PMCPMC9817247.

525 26. Wada Y, Shimada M, Murano T, Takamaru H, Morine Y, Ikemoto T, et al. A Liquid Biopsy Assay for
526 Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. Gastroenterology.
527 2021;161(1):151-62.e1. Epub 2021/04/06. doi: 10.1053/j.gastro.2021.03.062. PubMed PMID:
528 33819484; PubMed Central PMCID: PMCPMC10360659.

529 27. Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends in
530 genetics : TIG. 2021;37(11):1012-27. Epub 2021/06/15. doi: 10.1016/j.tig.2021.05.002. PubMed PMID:
531 34120771.

532 28. Chang SC, Liew PL, Ansar M, Lin SY, Wang SC, Hung CS, et al. Hypermethylation and decreased

533 expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor 534 prognosis, and early recurrence prediction. Clinical epigenetics. 2020;12(1):67. Epub 2020/05/14. doi: 535 10.1186/s13148-020-00855-z. PubMed PMID: 32398064; PubMed Central PMCID: PMCPMC7218647.

536 29. Yang R, Zhang G, Dong Z, Wang S, Li Y, Lian F, et al. Homeobox A3 and KDM6A cooperate in 537 transcriptional control of aerobic glycolysis and glioblastoma progression. Neuro-oncology. 538 2023;25(4):635-47. Epub 2022/10/11. doi: 10.1093/neuonc/noac231. PubMed PMID: 36215227; 539 PubMed Central PMCID: PMCPMC10076951.

540 30. Hata S, Pastor Peidro A, Panic M, Liu P, Atorino E, Funaya C, et al. The balance between KIFC3 and 541 EG5 tetrameric kinesins controls the onset of mitotic spindle assembly. Nat Cell Biol. 2019;21(9):1138-542 51. Epub 2019/09/05. doi: 10.1038/s41556-019-0382-6. PubMed PMID: 31481795.

543 31. Zhang T, Chen S, Peng Y, Wang C, Cheng X, Zhao R, et al. NOVA1-Mediated SORBS2 Isoform 544 Promotes Colorectal Cancer Migration by Activating the Notch Pathway. Frontiers in cell and 545 developmental biology. 2021;9:673873. Epub 2021/10/26. doi: 10.3389/fcell.2021.673873. PubMed 546 PMID: 34692669; PubMed Central PMCID: PMCPMC8531477.

547 32. Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, et al. Quantitative evidence for early 548 metastatic seeding in colorectal cancer. Nature genetics. 2019;51(7):1113-22. Epub 2019/06/19. doi: 549 10.1038/s41588-019-0423-x. PubMed PMID: 31209394; PubMed Central PMCID: PMCPMC6982526.

550 33. Wang H, Gong P, Chen T, Gao S, Wu Z, Wang X, et al. Colorectal Cancer Stem Cell States 551 Uncovered by Simultaneous Single-Cell Analysis of Transcriptome and Telomeres. Advanced science 552 (Weinheim, Baden-Wurttemberg, Germany). 2021;8(8):2004320. Epub 2021/04/27. doi: 553 10.1002/advs.202004320. PubMed PMID: 33898197; PubMed Central PMCID: PMCPMC8061397.

554 34. Feng D, Gao P, Henley N, Dubuissez M, Chen N, Laurin LP, et al. SMOC2 promotes an epithelial-555 mesenchymal transition and a pro-metastatic phenotype in epithelial cells of renal cell carcinoma 556 origin. Cell death & disease. 2022;13(7):639. Epub 2022/07/23. doi: 10.1038/s41419-022-05059-2. 557 PubMed PMID: 35869056; PubMed Central PMCID: PMCPMC9307531.

558 35. Lee Y, Dho SH, Lee J, Hwang JH, Kim M, Choi WY, et al. Hypermethylation of PDX1, EN2, and MSX1 559 predicts the prognosis of colorectal cancer. Experimental & molecular medicine. 2022;54(2):156-68. 560 Epub 2022/02/17. doi: 10.1038/s12276-022-00731-1. PubMed PMID: 35169223; PubMed Central 561 PMCID: PMCPMC8894425 interests.

562 36. Wan J, Su Y, Song Q, Tung B, Oyinlade O, Liu S, et al. Methylated cis-regulatory elements mediate 563 KLF4-dependent gene transactivation and cell migration. eLife. 2017;6. Epub 2017/05/30. doi: 564 10.7554/eLife.20068. PubMed PMID: 28553926; PubMed Central PMCID: PMCPMC5466421.

#### 566 Figure Legends

567 Figure 1. Flow diagram of the study.

568

Figure 2. Development and validation of tissue diagnosis model based on the 27 CRC-569 570 specific DMRs. (A) The use of ROC curve analysis to assess the performance of the tissue diagnostic model in differentiating CRC patients from normal individuals of the training 571 572 cohort (51 tissues we collected). (B-C) The use of ROC curve analysis to assess the performance of the tissue diagnostic model in differentiating CRC patients from normal 573 individuals(B) and distinguish AA from Normal subjects (C) in tissue validation cohort 574 1(GSE 48684 dataset). (D-E) The sensitivity and specificity of the diagnosis model in the 575 tissue training(D) and validation cohort 1(E). 576

577

578 Figure 3. Development and validation of a plasma diagnosis model based on the 27 CRCspecific DMRs. (A-B) Heatmap illustrating the DMRs between CRC and advanced adenoma 579 580 and healthy controls in the training (A) and validation cohort (B). (C) The use of ROC curve 581 analysis to assess the performance of the diagnosis model in differentiating CRC patients from normal individuals of the training cohort. (D) The use of ROC curve analysis to evaluate 582 the performance of the diagnosis model in differentiating CRC patients from normal 583 584 individuals of the validation cohort. (E-G) In the validation cohort, the performance of the diagnosis model in differentiating early-stage CRC (0-II) from normal individuals (E); in 585 differentiating advanced-stage CRC (III-IV) from normal individuals (F); in differentiating 586 587 AA from normal individuals (G). (H) Methylation scores of Normal , AA and CRC

588	individuals generated from the diagnosis model in the training and validation cohort (The
589	dashed line represents the cutoff value). (I) The sensitivity and specificity of the diagnosis
590	model stratified by stages in the training and validation cohort. Abbreviations: DMRs,
591	differential methylated regions; ROC, receiver operating characteristic; AA, advanced
592	adenoma; CRC, colorectal cancer.

593

Figure 4. External validation of plasma diagnosis model. (A-C) In the external validation cohort, the performance of the diagnosis model in differentiating early-stage CRC (0-II) from normal individuals (A); in differentiating AA from normal individuals (B); in differentiating NAA from normal individuals (C). (D) Methylation scores of Normal, NAA, AA and CRC (0-II) individuals generated from the diagnosis model in the external validation cohort (The dashed line represents the cutoff value). (E) The sensitivity and specificity of the diagnostic model for NAA, AA, and CRC in the external validation cohort.

601

602 Figure 5. Development and validation of a plasma-based metastasis model and a plasmabased prognosis model. (A-B) The methylation scores generated by the diagnosis model for 603 604 CRC patients across various M stages (A) and different disease stages (B). (C) ROC curve analysis was performed to assess the performance of 27 DMRs methylation scores generated 605 by the diagnosis model in distinguishing M1-CRC patients from M0-CRC patients in the 606 training (AUC = 0.969) and validation (AUC = 0.955) cohorts. (D) ROC analysis evaluates 607 the performance of 27 DMRs methylation scores generated by the diagnosis model in 608 609 predicting the prognosis of CRC patients. (E) Kaplan-Meier survival curves comparing OS 26

610	between the high-risk CRC group and low-risk CRC group of prognosis model in the training
611	cohort and validation cohort. (F, H) Metastasis and prognosis prediction of the training and
612	validation patitients( $n = 88$ ). The black dotted line at the cutoff value divides the patients into
613	high-risk and low-risk groups. Yellow circles and gray circles represent patients without
614	distant metastasis and with distant metastasis, respectively (F). Yellow circles and gray circles
615	represent patients survived and deceased, respectively (H). (G, I) The proportion of
616	metastasis and deceased is higher in the high-risk group. The p-value was calculated using a
617	two-sided Fisher's exact test. Abbreviations: DMRs, differential methylated regions; ROC,
618	receiver operating characteristic; M1-CRC, colorectal cancer with distant metastasis; M0-
619	CRC, colorectal cancer without distant metastasis; AUC, the area under the curve.
620	
621	Figure 6. Methylation scores of paired tissue and plasma samples. (A) The methylation scores
622	of tissues from Normal, AA, CRC 0-II, CRC III-IV individuals. (B) The methylation scores of
623	blood samples from Normal, AA, CRC 0-II, CRC III-IV individuals. (C) The mechanism
624	diagram interpreting the methylation scores changes of tissue and plasma across different
625	populations.

#### Figure 1







#### Figure 3



Training cohort		Predicted				
	Total	Negative	Positive	Sensitivity	Specificity	
Normal	33	28	5		0.85	
0-11	25	5	20	0.80		
III-IV	26	2	24	0.92		
Tumor	51	7	44	0.86		

Validation cohort		Predicted				
	Total	Negative	Positive	Sensitivity	Specificity	
Normal	14	13	1	2	0.93	
AA	37	21	16	0.43		
0-11	15	5	10	0.67		
III-IV	15	0	15	1		
Tumor	30	5	25	0.83		



638



